The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
The FDA is evaluating the regulation of specific peptides amid growing demand. We break down the science, the risks, and the clinical implications.
The federal government has extended its commitment to fund GLP-1 obesity medications through 2027, shifting away from private insurer mandates to protect seniors from premium hikes.
As GLP-1 medications like Ozempic and Wegovy change dietary habits, U.S. farmers are pivoting to pulse crops to meet the surging demand for high-protein foods.
A new study in Obesity Pillars suggests that while GLP-1 drugs aid weight loss, they may impact sexual desire through brain chemistry. Here is what you need to know.
A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.
Is your GLP-1 medication affecting your mood? Discover the science behind anhedonia, the 'Ozempic personality' phenomenon, and what experts say about dopamine and metabolic health.
A leading gynaecologist at Aston Medical School is probing whether GLP-1 drugs like Ozempic and Mounjaro could transform care for women with PCOS. With a £60,000 NHS grant, Dr Shagaf Bakour aims to evaluate their effects on metabolic health and fertility. This investigation highlights hope for better treatment pathways amid rising interest in these weight loss jabs.
New research presented at Digestive Disease Week 2026 suggests a minimally invasive 'gut reset' procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Ozempic and Wegovy. The findings address a major challenge in obesity treatment: weight regain after stopping therapy.
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
